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1 INTRODUCTION 
Thirteen hadron beam therapy facilities began operation 
between 1990 and 2001 - 5 in Europe, 4 in North Amer- 
ica, 3 in Japan, and 1 in South Africa [l]. Ten of them 
irradiate tumors with protons, 2 with Carbon- 12 ions, and 
1 with both protons and Carbon-12. The facility with the 
highest patient throughput - a total of 6 174 patients in 11 
years and as many as 150 patient treatments per day -is the 
Loma Linda University Medical Center, which uses a weak 
focusing slow cycling synchrotxon to accelerate beam for 
delivery to passive scattering nozzles at the end of rotatable 
gantries [2, 3,4]. The Rapid Cycling Medical Synchrotron 
(RCMS) is a second generation synchrotron that, by con- 
trast with the Loma Linda synchrotron, is strong focusing 
and rapid cycling, with a repetition rate of 30 Hz [5, 6, 71. 
Primary parameters for the RCMS are listed in Table 1. 
Table 1: Primary parameters of the RCMS facility. 
Minlmax extraction energy [MeV] 701250 
Repetition rate [Hz] 30 
Maximum protons per bunch 1.7 x 109 
Average protons per bunch 0.3 x 109 
Maximum flux, [protons/min] 3.0 x 1012 
Average scanning flux, [protons/min] 0.5 x 1012 
Ave. dose rate (250 MeV) [Gy-liter/min] 20 
Vert. beam size (250 MeV) [mm] 0.9 
Total horz. size (250 MeV) [mm] 2.5 
Cumulative total from 
6 beam pulses 
/ 
10 20 
Penetration depth in water [cm] 
30 
Figure 1: Spread out Bragg peak from 6 beam pulses. 
Figure 2: Simulated dose to a 6’cm tumor in a 20 cm phan- 
tom. The collateral dose is much more with beam delivery 
from one angle (LEFT) than from many angles (RIGHT). 
2 PATIENT TREATMENT PHYSICS 
Proton therapy is an effective and non-invasive way to 
treat tumors deep within the body because the protons de- 
liver most of their dose just before stopping, in the Bragg 
peak. Figure 1 shows how the longitudinal dose from mul- 
tiple beam pulses can be added up to deliver a total dose 
that is flat over the depth of the tumor. In this case 6 pulses 
with different energies and an RMS energy spread of 2 
MeV deliver a dose that is flat to 1% over a plateau about 5 
cm long. However, Figure 1 also shows that if all the beam 
comes from the same direction - in a “single field” treat- 
ment - then the collateral dose at the surface of the patient 
is still approximately 30% of the dose at the tumor. 
This is illustrated on the left of Figure 2, which shows 
the integrated dose delivered to a hypothetical tumor in a 
cylindrical phantom. The collateral dose is enormously re- 
duced with tomotherapy, when the therapeutic dose is de- 
livered from many different angles - the collateral dose on 
the right of Figure 2 is barely visible. Figure 3 shows that 
the dose at the surface of the patient is reduced to about 5% 
with tomotherapy. This is much less than the 30% value 
for single field irradiation with protons, and about a factor 
of 10 less than the collateral dose from X-rays delivered 
with Intensity Modulated Radiation Therapy (IMRT) from 
many angles, as also shown in Figure 3. 
The effects of multiple scattering and energy straggling 
are important. Figure 4 shows that the transverse beam size 
is dominated by multiple scattering, if the incoming paral- 
lel beam size is at the 1 mm level or less [8]. Similarly, the 
RMS energy spread of 2 MeV that was used in Figure 1 is 
typical, even for a mono-energetic incoming beam. 
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Figure 3: Integrated dose from tomotherapy of a 6 cm tu- 
mor using protons and X-rays. The collateral dose with 
protons is an order magnitude less than with X-rays. 
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Figure 4: Transverse beam size due to multiple scattering. 
3 CLINICAL REQUIREMENTS ON THE 
ACCELERATOR 
The most challenging top level requirements for acceler- 
ator performance in a proton therapy facility follow from 
the clinical goal of very low collateral dose during 3-D 
stereo-tactic therapy, as described above. 
Raster scanning sharp beams. The sharpest possible 
pencil beam must be painted in 3-D onto an irregularly 
shaped tumor from each of many treatment angles. A raster 
scanning system uses horizontal and vertical steering mag- 
nets just before the nozzle at the end of a gantry to move 
the narrow beam transversely, while the energy is varied for 
depth control. This is demonstrated in Figures 2 and 1, re- 
spectively. In contrast, passive scattering nozzles severely 
inhibit multiple field treatment, since a beam spreader is 
used to make a broad uniform transverse beam that in- 
evitably also has an artificially large energy spread. The 
beam from a passive scattering nozzle is unwieldy, has high 
losses, generates many neutrons, and requires a different 
collimator profile for each treatment angle. 
Energy flexibility. It is necessary to be able to change 
the energy of the extracted beam rapidly, over a large range 
of closely spaced values, in order to rapidly paint the tu- 
mor from many angles. This requires robust and repeat- 
able “fast extraction” of all the beam on a single turn of 
the accelerator. The extraction energy of the RCMS can 
be changed at a 30 Hz rate (on each cycle) over the en- 
tire range from 70 MeV to 250 MeV. In practice the max- 
imum rate of change of delivered beam energy (at least 5 
MeVls) is set by how quickly the beam delivery magnets 
can change current. In contrast, slow extracted beam re- 
quires careful tuning, and expert feedback systems, at each 
of a small number of established extraction energies. 
High beam flux. The largest number of protons need 
to delivered per minute, in order to treat the largest tumors 
in the shortest times. This is closely related to the need for 
rapid acceleration, since the number of protons that a syn- 
chrotron can accelerate in each cycle is limited by the space 
charge effect [3,4]. Thus, the RCMS with a repetition rate 
of 30 Hz delivers a average flux much higher than syn- 
chrotrons with an acceleration period of a few seconds [9]. 
In 250 MeV operation the RCMS delivers as much as 20 
Gy per minute to a 1 liter tumor. The usual dose per daily 
treatment is a few Gy. 
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Figure 5: Sample layout of the RCMS facility. 
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Figure 6: A light weight separated function gantry. 
4 RCMS ADVANTAGES 
Figure 5 shows a sample RCMS layout, including only 
the first gantry room. Figure 6 shows the geometry of 
a gantry with separated function magnets. Note that if 
there are 4 gantries, then there are about twice as many 
gantry bending magnets - 720 degrees worth - as there 
are in the synchrotron itself. Both the synchrotron and the 
gantry optics use strong focusing to make sharply focused 
beams [lo]. Small beam sizes are not only a clinical ne- 
cessity, but also enable inexpensive gantries, since small 
beams permit the use of small, lightweight, magnets which 
are economical to operate. 
Strong focusing optics and small beams are options only 
available to synchrotron based facilities, and not to cy- 
clotrons [4]). Synchrotrons have further advantages. They 
consume less than half the power of equivalent cyclotrons, 
reducing both operating and capital infrastructure costs. 
Synchrotrons are much more efficient in delivering beam - 
a much higher percentage of beam gets from the source to 
the patient. This is especially true of a fast extraction syn- 
chrotron like the RCMS. High efficiency means that much 
less residual radio-activity and far fewer neutrons are gen- 
erated, so that less shielding is required and building costs 
are reduced. It also means that a synchrotron facility is eas- 
ier to handle, since there is instant access for maintenance, 
and less need to monitor operator and technician dosimetry. 
Finally, even a weak focusing synchrotron is much lighter 
than the single massive magnet in an equivalent cyclotron. 
This also greatly reduces the cost of the building founda- 
tions. 
The RCMS design chooses simple proven technologies 
to ensure that the proton therapy facility will have high re- 
liability and availability. For example, rapid cycling syn- 
chrotrons with resonant main magnet power supplies have 
been in operation at many locations, worldwide, for 40 
years. Secondly, fast extraction on a single turn is robust 
and reliable, and avoids the possibility of dumping large 
amounts of stored beam into a patient. Third, the injection 
energy is relatively high, at 7 MeV. Finally, and most all of 
all, strong focusing is used throughout, to keep the beam 
sharply focused and well under control. 
5 WMMARY 
Proton tomotherapy - beam delivery from many angles 
- enables ultra-low collateral doses in precision 3-D stereo- 
tactic tumor therapy. The simplicity, reliability, and flexi- 
bility of the RCMS design all contribute directly to supe- 
rior clinical performance in tomotherapy, and in the treat- 
ment of the largest tumors in the shortest times. Building, 
gantry, infrastructure, and operating costs should all be in- 
cluded when comparing medical synchrotron and cyclotron 
designs. 
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